After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
NKTR belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Nektar Therapeutics is $417.63M. A total of 0.94 million shares were traded on the day, compared to an average of 1.73M shares.
In the most recent transaction, Zalevsky Jonathan sold 10,712 shares of NKTR for 0.67 per share on May 19 ’25. After the transaction, the Chief R&D Officer now owns 305,892 company shares. In a previous transaction on May 19 ’25, Wilson Mark Andrew sold 9,996 shares at 0.67 per share. NKTR shares that Chief Legal Officer owns now total 314,296.
Among the insiders who sold shares, ROBIN HOWARD W disposed of 23,208 shares on May 19 ’25 at a per-share price of $0.67. This resulted in the President & CEO holding 1,063,693 shares of NKTR after the transaction. In another insider transaction, Zalevsky Jonathan bought 10,712 shares at $0.67 per share on May 19 ’25.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, NKTR has a high of $37.38 and a low of $6.48.
As of this writing, NKTR has an earnings estimate of -$2.79 per share for the current quarter. EPS was calculated based on a consensus of 3.0 estimates, with a high estimate of -$2.55 per share and a lower estimate of -$3.0.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. NKTR’s latest balance sheet shows that the firm has $733.96M in Cash & Short Term Investments as of fiscal 2021. There were $143.18M in debt and $85.20M in liabilities at the time. Its Book Value Per Share was $1.11, while its Total Shareholder’s Equity was $679.51M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NKTR is Buy with a score of 4.25.
